Cumming Global Centre for Pandemic Therapeutics receives $5 million grant from The Ian Potter Foundation
Posted: 28 June 2023 The Cumming Global Centre for Pandemic Therapeutics (Cumming Global Centre) has received a generous $5 million seed grant from one of Australia’s leading philanthropic organisations, The Ian Potter Foundation. Launched in August 2022, the Doherty Institute’s Cumming…
Excellent Clinical Data For SubB2M/CA15-3 Breast Cancer Test
Posted: 27 July 2023 INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company), a developer of next-generation exosome solutions and precision diagnostics, is pleased to announce excellent results from an independent clinical validation study of its SubB2M/CA15-3 test for breast…
Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission
Posted: 27 June 2023 The Board of Directors of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has given the green light for the company to proceed with IMM-529 cGMP manufacturing for the treatment of a form of gastrointestinal disease. Directors have also approved…
Australian invention for potential treatment of anxiety disorders initiates Phase 2a Clinical Trial
Posted: 27 July 2023 A unique drug delivery platform developed by Monash University researchers in partnership with PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), has reached another exciting milestone, with the initiation of a Phase 2a clinical trial of LYT-300…
Avecho passes two-year stability milestone for its pharmaceutical CBD soft-gel capsule
Posted: 27 June 2023 Avecho Biotechnology Limited (ASX:AVE, “Avecho”, or “the Company”) has today announced it has passed a crucial two–year stability point milestone for its TPM®–enhanced cannabidiol (“CBD”) soft–gel capsule. Cannabinoids are susceptible to degradation from a…
Imagion set to complete the MagSense HER2 Phase 1 Study
Posted: 21 June 2023 Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that the MagSense® HER2 imaging agent Phase 1 study (IBI10103) has achieved its enrolment…
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Posted: 21 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,680,104) by the United States Patent Office.…
Rhythm Continues Platform Expansion Program for Other Cancers
Posted: 21 June 2023 Transformative cancer diagnostic technology, Rhythm Biosciences Ltd is pleased to provide an update regarding the technical feasibility pipeline expansion initiatives/opportunities. As previously announced, the Company has identified several other critical cancers where it can…
Vaccine Innovation Trends Report: Global Vaccine Research and Development Pipeline and Delivery Implications
Posted: 19 June 2023 Vaccines are essential to global public health — available to prevent more than 20 diseases, vaccines avert 3.5 to 5 million deaths each year and combat emerging infectious diseases and the spread of microbial…
U.S. FDA Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Posted: 19 June 2023 Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the Phase 3 VALOR-HCM study to the U.S.…
Pioneering radiotherapy treatment emerging as a new option for cancers spread to lungs
Posted: 19 June 2023 A pioneering radiotherapy treatment developed at Peter Mac is emerging as a new treatment option for cancer that has spread to the lungs, following exciting results in a recent study. Long-term survival data is…
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
Posted: 19 June 2023 Telix today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of…
